A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

BACKGROUND: CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab reference product (RP; Remicade®). The aim of this study was to compare the 54-week efficacy, immunogenicity, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of CT-P13 and RP in patients with active rheumatoid arthri...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Dae Hyun, Racewicz, Artur, Brzezicki, Jan, Yatsyshyn, Roman, Arteaga, Edgardo Tobias, Baranauskaite, Asta, Abud-Mendoza, Carlos, Navarra, Sandra, Kadinov, Vladimir, Sariego, Irmgadt Goecke, Hong, Seung Suh, Lee, Sung Young, Park, Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818886/
https://www.ncbi.nlm.nih.gov/pubmed/27038608
http://dx.doi.org/10.1186/s13075-016-0981-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818886/
https://www.ncbi.nlm.nih.gov/pubmed/27038608
http://dx.doi.org/10.1186/s13075-016-0981-6

Ejemplares similares